Game-changing pan-TEAD inhibitor for solid tumours
Drug Target Review
JUNE 12, 2023
The system optimised the molecules that were most likely to succeed in terms of potency, metabolic stability, synthetic accessibility, and more. Prior to founding Insilico, Alex worked in senior roles at ATI Technologies (a GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, and the Biogerontology Research Foundation.
Let's personalize your content